Liver Masses: Radiological, Histopathological, and Immunohistochemical Correlation - A Retrospective Tertiary Care Hospital-Based Study
DOI:
https://doi.org/10.21276/apalm.3362Keywords:
Neoplasm, Radiology, Histopathology, Immunohistochemistry, Hepatocellular carcinoma, MetastasisAbstract
Background: Hepatic lesions consist of a wide range of abnormalities, including benign tumors, abscesses, primary malignancies, and metastatic tumors, each with distinctive histopathological and radiological findings. It is often challenging to differentially diagnose most metastatic lesions and some liver primaries based on clinical, radiological, and histopathological findings alone. Immunohistochemistry plays a crucial role in accurately diagnosing such lesions, which further aids clinicians in formulating an appropriate treatment plan.
Materials and Methods: The present cross-sectional retrospective study was conducted in the Department of Pathology at the American International Institute of Medical Sciences, Udaipur. Data from ultrasound-guided liver biopsies received in the department between January 2022 and October 2023 were collected. Immunohistochemical data for the respective cases were also gathered. Statistical analysis was performed using MedCalc software. A p-value of <0.05 was considered the cutoff for statistical significance..
Results: A total of 82 cases were included in the study. The mean age was 58.37 years. Of the 82 cases, 80 (97.5%) were malignant, and 2 (2.5%) were benign. Among the 80 malignant lesions, 10 (12.5%) were primary hepatic tumors, while 70 (87.5%) were metastatic tumors. Sensitivity, specificity, negative predictive value, positive predictive value, and diagnostic accuracy were 50.00%, 100.00%, 98.77%, 100.00%, and 98.78%, respectively. The p-value was statistically significant (p < 0.024).
Conclusion: Despite various advancements in imaging techniques, histopathological assessment followed by immunohistochemistry remains the gold standard for accurately diagnosing liver lesions. The integration and correlation of both radiological and pathological findings will provide better diagnostic accuracy, leading to improved patient care, prognosis, and overall survival.
References
Babar K, Salah-Ud-Din H, Tanvir I, Shahbaz B, Bakkar MA, Ali MS, et al. Diagnostic correlation of histopathological and radiological findings in hepatic lesions keeping histopathology as gold standard. Pak J Med Health Sci. 2019;13(2):279-81.
Khalifa A, Sasso R, Rockey DC. Role of liver biopsy in assessment of radiologically identified liver masses. Dig Dis Sci. 2022;67(1):337-43.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.
Rastogi A. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma. World J Gastroenterol. 2018;24(35):4000-13.
Sunnapwar A, Katre R, Policarpio-Nicolas M, Katabathina V, Erian M. Imaging of rare primary malignant hepatic tumors in adults with histopathological correlation. J Comput Assist Tomogr. 2016;40(3):452-62.
Khadim MT, Jamal S, Ali Z, Akhtar F, Atique M, Sarfaraz T, et al. Diagnostic challenges and role of immunohistochemistry in metastatic liver disease. Asian Pac J Cancer Prev. 2011;12:373-6.
Ibrahim A, Sharma V, Lamghare D, Dhete V. A study of correlation of USG findings of liver mass lesions with histopathological diagnosis. Indian J Basic Appl Med Res. 2017;6(2):37-41.
Geller SA, Dhall D, Alsabeh R. Application of immunohistochemistry to liver and gastrointestinal neoplasms: liver, stomach, colon and pancreas. Arch Pathol Lab Med. 2008;132(3):490-9.
Ali W, Saba K, Zaidi NR, Majeed T, Bukhari MH. Diagnostic accuracy of color Doppler in diagnosis of hepatocellular carcinoma taking histopathology as gold standard. J Biomed Sci Eng. 2013;6(6):609-16.
Kudo M. Immune checkpoint blockade in hepatocellular carcinoma: 2017 update. Liver Cancer. 2016;6:1-12.
Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alfa-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282-96.
Djuric U, Zadeh G, Aldape K, Diamandis P. Precision histology: how deep learning is poised to revitalize histomorphology for personalized cancer care. NPJ Precis Oncol. 2017;1:22.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Swarneet Bhamra, Priyanka Tiwari, Bharat Gupta, Preeti Agrawal
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
